(Q40358404)

19 September 2017

title

Respective efficacy of gonadotrophins should be the heart of the debate (English)

1 reference

19 September 2017

Emperaire JC

1

1 reference

19 September 2017

publication date

1 November 2005

1 reference

Reproductive BioMedicine Online

19 September 2017

published in

1 reference

19 September 2017

volume

11

1 reference

19 September 2017

issue

5

1 reference

19 September 2017

page(s)

540-542

1 reference

Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961156-X

7 January 2021

Meta-analysis of recombinant versus urinary-derived FSH: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961156-X

7 January 2021

In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961156-X

7 January 2021

Recombinant gonadotrophins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961156-X

7 January 2021

Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961156-X

7 January 2021

Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961156-X

7 January 2021

10.1016/S1472-6483(10)61156-X

Identifiers

DOI

1 reference

19 September 2017

1 reference